

Professionele biografie van Marino Garcia

De heer Garcia is sinds november 2021 President, Chief Executive Officer, en lid van de Raad van Bestuur van Dianthus Therapeutics (Nasdaq: DNTH). Hij vervoegde Dianthus vóór de Series A financieringsronde van de vennootschap en leidde diens transformatie tot een publiek genoteerd bedrijf met drie programma's in de klinische ontwikkelingsfase en meer dan USD 1,6 miljard opgehaald kapitaal. Vóór Dianthus, was Marino actief als *Senior Vice President, Corporate and Business Development* bij Zealand Pharma A/S, een biotechnologiebedrijf, van oktober 2018 tot oktober 2021. Marino werkte voordien als *Executive Vice President, Chief Strategy Officer* bij Synergy Pharmaceuticals van 2014 tot 2018. Vóór Synergy, was Marino actief als *Head of Business Development* bij Aptalis Pharma toen het werd overgenomen door Forest Laboratories (nu Allergan, een AbbVie Company) in 2014. Voordien was hij ook *Vice President, US Commercial Operations and Global New Product Development* bij Aspreva Pharmaceuticals, dat werd overgenomen door Vifor Pharma in 2007. Aspreva ontwikkelde CellCept (mycophenolate mofetil) voor verschillende auto-immuunziektes, waaronder Lupus Nephritis, Myasthenia Gravis en Pemphigus Vulgaris. Marino startte zijn carrière in verschillende commerciële en strategische functies bij grote, internationale biofarmaceutische bedrijven zoals Merck & Co., Pfizer Inc. and Eli Lilly and Co. Marino behaalde zijn M.B.A. aan de Ivey Business School van de Western University in London, Ontario en zijn Bachelor of Commerce aan Concordia University in Montreal, Quebec.

Professional Biography of Marino Garcia

Mr. Garcia has served as President, Chief Executive Officer, and member of the Board of Directors of Dianthus Therapeutics (Nasdaq: DNTH) since November 2021. He joined Dianthus prior to the company's Series A financing and has led its transformation into a publicly traded, clinical-stage company with three product candidates in development and more than \$1.6 billion in capital raised to date. Prior to joining Dianthus, Marino served as Senior Vice President, Corporate and Business Development at Zealand Pharma A/S, a biotechnology company, from October 2018 to October 2021. Marino previously served as Executive Vice President, Chief Strategy Officer at Synergy Pharmaceuticals from 2014 to 2018. Prior to Synergy, Marino served as Head of Business Development for Aptalis Pharma when it was acquired by Forest Laboratories (now Allergan, an AbbVie Company) in 2014. Previously he served as Vice President, US Commercial Operations and Global New Product Development at Aspreva Pharmaceuticals, which was acquired by Vifor Pharma in 2007. Aspreva was developing CellCept (mycophenolate mofetil) for a range of autoimmune diseases, including Lupus Nephritis, Myasthenia Gravis, and Pemphigus Vulgaris. Marino started his career in various commercial and strategic roles at large, multinational biopharmaceutical companies, including Merck & Co., Pfizer Inc. and Eli Lilly and Co. Marino received his M.B.A. from the Ivey Business School at Western University in London, Ontario and his Bachelor of Commerce from Concordia University in Montreal, Quebec.